论文部分内容阅读
An IMRT/VMAT Technique for Nonsmall Cell Lung Cancer
【机 构】
：
Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China
【出 处】
：
2015年北京放射肿瘤年会
【发表日期】
：
2016年5期
其他文献
本研究主要是评价接受根治性切除和辅助化疗的pⅢA-N2期非小细胞肺癌(NSCLC)患者,进一步接受术后三维适形放疗(3DCRT)对生存和复发模式的影响.从2009.1.1到2013.5.31,所有患者均接受根治性肺叶切除的pⅢA-N2NSCLC患者在完成4周期以顺铂为基础的联合化疗后进行全面复查,未出现肿瘤复发转移的患者被随机分入术后放疗(PORT)组和对照组.入组≥2年的患者纳入本次分析.POR
分析Ⅳ期肺腺癌采用选择性放疗联合/或靶向治疗的疗效.分析本院2009年6月1日起,Ⅳ期肺腺癌接受肺原发病灶和关键转移病灶选择性放疗联合/或靶向治疗的患者共50例,其中单纯应用小分子靶向药物(表皮生长因子受体酪氨酸激酶抑制剂,EGFR-TKI)7例,单纯选择性放疗患者18例,选择性放疗联合EGFR-TKI25例.小分子靶向药物使用时间1～44月,中位时间14月.放疗方案为：体部伽马刀技术,70％等剂
Objective: To evaluate the long-term survival outcomes and toxicity of a larger series of patients with non-metastatic T4 classification nasopharyngeal carcinoma (NPC) treated with intensity-modulated
Clinical value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in evaluat
For patients with locoregionally advanced nasopharyngeal carcinoma (NPC), radiotherapy, chemotherapy and even targeted therapy are widely accepted treatments.These treatments, although they mostly ach
Background.The purpose of this study was to determine the features of the eldedy patient with nasopharyngeal carcinoma (NPC).Methods.The medical records of 212 patients with NPC, aged >65 years, and r
会议
Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multi
会议
染色质解旋酶/ATP酶的DNA结合蛋白1样基因(CHD1L)是一种新近被证实与在许多实体瘤中表达增多的致癌基因,它定位于第1号染色体q21区.CHD1L在肝细胞癌和其他肿瘤中的功能性研究提示,该基因在肿瘤形成过程中可以引起细胞增殖、调节G1/S过渡期并且可以抑制细胞凋亡.CHD1L活化的潜在机制可能是通过结合凋亡蛋白Nur77,或通过上调CHD1L调控的靶基因(如ARHGEF9、SPOCK1或TC
Computed Tomography (CT)-guided Interstitial Permanent Implantation of 125I Seeds for Refractory Che
To evaluate the efficacy and safety of 125I seeds implantation for refractory chest wall (CW)metastasis or recurrence under CT guidance.In addition we assessed initial data obtained on the therapeutic